GLPG4716 not checked
Molecure S.A. · Lakefront Biotherapeutics NV · OATD-01
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pulmonary Sarcoidosis
- Main trialPhase 2
- “This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.”In the company’s words, NCT06205121 on ClinicalTrials.gov
- Other names
- OATD-01
Other drugs for Pulmonary Sarcoidosis
- XTMAB-16Xentria, Inc. · Phase 2
- TulisokibartMerck & Co. · Phase 2
Coming up1
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Aug 2027 | Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis | |
| Phase 1Completed | 13 Nov 2021 | Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects | |
| Phase 1Completed | 9 May 2022 | Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026